145 results on '"Kadambi, Vivek"'
Search Results
2. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
3. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices
4. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database
5. Array Transcription Profiling: Molecular Phenotyping of Rodent Cardiovascular Models
6. Genetic Alterations and Modeling of Cardiovascular Physiology
7. Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
8. Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development
9. Chapter 8. Cardiac Toxicity Prediction: To Simplify, or to Integrate, that is the Question
10. Update on Customized Laser Assisted Filtration Surgery (CLAFS) using a Solid State uv Laser
11. Thermal Keratoplasty for Hyperopic Correction Using a Focused Diode Laser—A New Modality
12. Customized Laser-assisted Filtration Surgery (CLAFS) Using a Solid-state UV Laser
13. A New System (DTK-Plus) for Thermal Keratoplasty Using IR Lasers
14. Modulation of force-frequency relation by phospholamban in genetically engineered mice
15. Model for Proteasome Inhibition Associated Peripheral Neuropathy
16. Genetic Alterations and Modeling of Cardiovascular Physiology
17. Array Transcription Profiling: Molecular Phenotyping of Rodent Cardiovascular Models
18. Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic β-adrenergic stimulation
19. Functional integrity of lacrimal drainage apparatus by radionuclide dacryocystography
20. Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6tx00220j
21. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins
22. Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma
23. Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development
24. Cardiac-specific Overexpression of Phospholamban Alters Calcium Kinetics and Resultant Cardiomyocyte Mechanics in Transgenic Mice
25. Role of PRL-3, a Human Muscle-Specific Tyrosine Phosphatase, in Angiotensin-II Signaling
26. Cardiac-specific Overexpression of Calsequestrin Results in Left Ventricular Hypertrophy, Depressed Force–frequency Relation and Pulsus Alternans In Vivo
27. Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development.
28. Review of an electronic health record model to facilitate remote patient management in metabolic and lifestyle diseases
29. Influence of Transgenic Overexpression of Phospholamban on Postextrasystolic Potentiation
30. Influence of sarcoplasmic reticulum calcium loading on mechanical and relaxation restitution
31. Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants
32. MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
33. Predictive toxicology approaches for small molecule oncology drugs
34. Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
35. O–255 - Transgenic approaches to elucidate the physiological significance of phospholamban phosphorylation sites under β-adrenergic stimulation
36. Vedolizumab Does Not Affect the Suppressive Activity of Gut-homing T Regulatory Cells
37. Proteasome Inhibitors Do Not Inhibit the Serine Protease HtrA2/Omi
38. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
39. Cardiotoxicity in cancer therapeutics: What's the limit?
40. Oxytocin, vasopressin, and QT prolongation: Determination of an unknown mechanism of action
41. Understanding a hERG anomoly: One class of compounds challenges the theory
42. EXPANDING THE SCOPE OF THE hERG BINDING ASSAY: hERG TRAFFICKING AND METABOLITE TESTING
43. Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists
44. Interactions Between Phospholamban and β-Adrenergic Drive May Lead to Cardiomyopathy and Early Mortality
45. Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/OmiElectronic supplementary information (ESI) available. See DOI: 10.1039/c6tx00220j
46. Phospholamban Is Present in Endothelial Cells and Modulates Endothelium-Dependent Relaxation
47. Transgenic approaches to elucidate the physiological significance of phospholamban phosphorylation sites under β-adrenergic stimulation
48. Genetically engineered mice: Model systems for left ventricular failure
49. Pentameric Assembly of Phospholamban Facilitates Inhibition of Cardiac Function in Vivo
50. Cardiac-specific Overexpression of Mouse Cardiac Calsequestrin Is Associated with Depressed Cardiovascular Function and Hypertrophy in Transgenic Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.